Zealand Pharma A/S (ZLDPF)
| Previous close | 29.65 |
| Open | 29.65 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 29.65 - 29.65 |
| 52-week range | 27.85 - 41.42 |
| Volume | 100 |
| Avg. volume | 3 |
| Market cap | 1.333B |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.32 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 222.65 |
- GlobeNewswire
Total number of shares and voting rights in Zealand Pharma at September 30, 2021
Company announcement – No. 62 / 2021 Total number of shares and voting rights in Zealand Pharma at September 30, 2021 Copenhagen, DK and Boston, MA, September 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at
- GlobeNewswire
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 61 / 2021 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, DK and Boston, MA, U.S., September 10, 2021 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has received information on transactions in Zealand's shares
- GlobeNewswire
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Company announcement – No. 60 / 2021 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants Copenhagen, DK and Boston, MA, U.S. September 10, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 30,748 divided into 30,748 new shares with a nominal value of DKK 1 each. The
